MPPE1 and lymphoma: A strong antitumor activity was also observed when a nanobody against the cDC1 marker Clec9A was used as adapter in murine melanoma, breast carcinoma and lymphoma models and against human lymphoma in humanized mice without any detectable toxic side effects 164,169.